Prophylactic tranexamic acid and epsilon-aminocaproic acid for primary myocardial revascularization.
about
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusionAre antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials.Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysisContribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial.Pharmacological approaches to reducing allogeneic blood exposure.Prophylactic intraoperative tranexamic acid administration and postoperative blood loss after transapical aortic valve implantation.The safety and efficacy of "bloodless" cardiac surgery.Endpoints in clinical trials on transfusion requirements: the need for a structured approach.Topical tranexamic acid as a novel treatment for bleeding peptic ulcer: A randomised controlled trial.Acute arterial thrombosis associated with inadvertent high dose of tranexamic acidMajor transfusions remain frequent despite the generalized use of tranexamic acid: an audit of 3322 patients undergoing cardiac surgery.Evaluation and Comparison of Using Low-Dose Aprotinin and Tranexamic Acid in CABG: a Double Blind Randomized Clinical Trial.The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery.Preservation of collagen-induced whole blood platelet aggregation by tranexamic acid therapy in primary cardiac valve surgery.A family of textilinin genes, two of which encode proteins with antihaemorrhagic properties.
P2860
Q24235627-B2545285-6B0F-4B9D-88F4-D7ADEB59BB93Q24812624-30580EF9-DFDC-4B02-B3C8-F6F3673BF030Q26864678-9D4EA530-2CE9-4CE7-9495-1D74FE66B9C2Q33652707-712C024D-16F6-4D5B-B50A-3ACFBD23E81BQ35050993-AA4DA5E5-D927-46A7-9BB4-ABB981839C3AQ35368507-4E8E45C3-6DA1-4902-BABF-BA9078D88B5FQ36056765-1290EC1F-B438-41A0-88EF-20889AC4599EQ36179831-A4845C8A-53C5-4A19-85B8-372E16C033F3Q37113675-4557F1B7-F416-4EEA-B2AF-6A74C7241063Q37230373-3CDD10E1-48E7-4B46-BDC2-8C9252A66AD0Q38817197-CA67F823-F974-4EE7-BCF8-15DB25F5C9EEQ42212763-8EBA9E33-A82E-499B-AD97-E35147EFF9BBQ46690444-9EB01946-70B3-42CD-A761-6617B8D89C77Q51369937-3A52688B-B592-4AFB-9987-648D576D3CB2Q53744294-0FB51D55-8171-4D1A-89F4-0A798091E181
P2860
Prophylactic tranexamic acid and epsilon-aminocaproic acid for primary myocardial revascularization.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Prophylactic tranexamic acid a ...... myocardial revascularization.
@en
Prophylactic tranexamic acid a ...... myocardial revascularization.
@nl
type
label
Prophylactic tranexamic acid a ...... myocardial revascularization.
@en
Prophylactic tranexamic acid a ...... myocardial revascularization.
@nl
prefLabel
Prophylactic tranexamic acid a ...... myocardial revascularization.
@en
Prophylactic tranexamic acid a ...... myocardial revascularization.
@nl
P2093
P1476
Prophylactic tranexamic acid a ...... y myocardial revascularization
@en
P2093
P304
P356
10.1016/S0003-4975(97)01016-3
P407
P577
1998-02-01T00:00:00Z